FCA Venture Partners is pleased to announce the completion of fundraising for its sixth fund, FCA Venture Partners VI, on April 27th. The Fund closed with $55M of committed capital and has already made investments in five portfolio companies. Consistent with its predecessor fund, FCA VI will focus on early to growth stage companies in the healthcare IT and technology sectors with disruptive, scalable business models.

Clinical Ink, the pioneering provider of eSource and next-generation ePRO/eCOA solutions for clinical development, today announced that the private equity team at NovaQuest Capital Management, L.L.C. ("NovaQuest") has acquired a majority of the outstanding shares of the company from existing investors and provided a substantial infusion of additional growth capital. The deep clinical, operational, and financial resources of NovaQuest will allow Clinical Ink to aggressively pursue growth opportunities and fuel investment in new products and operational capabilities.

The Oncology space offers an attractive market opportunity for the rapidly growing number of cancer-focused startups. The transition to value-based reimbursement is fueling this market opportunity by pressuring providers to improve processes and reduce costs.

We are pleased to announce that two FCA portfolio companies were recently featured on David William's Health Business Blog podcast. 

Absolute Antibody Ltd., an Oxford, UK-based company with a vision to make recombinant antibody technology accessible to all, and Kerafast Inc., a Boston, MA-based company with a mission to facilitate access to unique laboratory-made reagents, today announced a merger of the two companies. The merger brings together two companies with a shared commitment to improving the selection of research tools available to the scientific community.

For the third consecutive year, ChartWise has been named a Category Leader in the Clinical Documentation Improvement Software segment in the 2018 Best in KLAS: Software & Services report. The prestigious and highly coveted Category Leader designation is reserved for vendor solutions that lead select market segments in which at least two products meet a minimum level of KLAS Konfidence.

My colleagues and I founded Procured Health in 2012 to assist hospitals and physicians in their efforts to make evidence-based and data-driven device selection and utilization decisions. Over time, as value-based care has become a reality, we’ve broadened our focus to more holistically guide clinicians and administrative leaders in not only devices but also in medication utilization. Additionally, we have launched new and innovative professional services. As a result, we felt our identity needed to better represent this expanded scope and mission. Watch a video to learn more about our unique clinical approach.

Please enjoy this report on the Outsourced Care Management Industry. This is an area of the healthcare industry that FCA is interested in investing in. The report was put together by Dillon Vess, who is currently completing his MBA at Vanderbilt.